Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | $75.62M |
| Net Income (Most Recent Fiscal Year) | $-72.70M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 52.69 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.24 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 12.09% |
| Net Margin (Trailing 12 Months) | 11.54% |
| Return on Equity (Trailing 12 Months) | 8.28% |
| Return on Assets (Trailing 12 Months) | 5.07% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.54 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.63 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.33 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.98 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.32 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 65.12M |
| Free Float | 60.62M |
| Market Capitalization | $1.10B |
| Average Volume (Last 20 Days) | 0.93M |
| Beta (Past 60 Months) | 1.60 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 79.96% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |